Skip to main content

Table 1 Baseline demographics of the per-protocol cohort for immunogenicity

From: Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults

Treatment groupa
Characteristic QIV LD QIV-AS LD TIV-AS TIV Total
Nb 104 104 104 105 417
Age (years)
Mean ± SD 38.6 ± 11.82 37.7 ± 12.30 36.7 ± 12.84 37.4 ± 12.51 37.6 ± 12.35
Median 38.0 37.0 33.5 36.0 36.0
Range (min–max) 19–59 18–59 18–59 18–59 18–59
Gender n(%)
Female 60 (57.7) 66 (63.5) 66 (63.5) 58 (55.2) 250 (60.0)
Male 44 (42.3) 38 (36.5) 38 (36.5) 47 (44.8) 167 (40.0)
Race n(%)
African heritage 1 (1.0) 0 0 0 1 (0.2)
White Caucasian 103 (99.0) 104 (100) 104 (100) 105 (100) 416 (99.8)
  1. a Groups were administered the quadrivalent influenza vaccine (QIV), the low-dose adjuvanted quadrivalent influenza vaccine (LD QIV-AS), the low-dose adjuvanted trivalent influenza vaccine (LD TIV-AS) or the trivalent influenza vaccine (TIV).
  2. b Abbreviations: N = total number of participants, n(%) = number (percentage) of participants with characteristic, min–max = minimum to maximum, SD = standard deviation.